Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours

Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours

Summary Background Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well‐differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1). Aim To...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical endocrinology (Oxford) 2014-06, Vol.80 (6), p.850-855
Hauptverfasser: Ramundo, V., Del Prete, M., Marotta, V., Marciello, F., Camera, L., Napolitano, V., De Luca, L., Circelli, L., Colantuoni, V., Di Sarno, A., Carratù, A. C., de Luca di Roseto, C., Colao, A., Faggiano, A.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Biological and medical sciences
Cell Differentiation
Disease Progression
Endocrine System - physiology
Endocrinopathies
Female
Fundamental and applied biological sciences. Psychology
Gastrins - blood
Gastroenterology. Liver. Pancreas. Abdomen
General aspects. Associated endocrine diseases. Endocrine paraneoplasic syndromes
Humans
Insulin - blood
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Multiple Endocrine Neoplasia Type 1 - complications
Multiple Endocrine Neoplasia Type 1 - drug therapy
Neuroendocrine Tumors - complications
Neuroendocrine Tumors - drug therapy
Octreotide - therapeutic use
Retrospective Studies
Somatostatin - chemistry
Time Factors
Treatment Outcome
Tumors
Vertebrates: endocrinology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well‐differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1). Aim To evaluate the efficacy of the long‐acting SSA octreotide in MEN1 patients with early‐stage duodeno‐pancreatic NETs. Patients and Methods Forty patients with MEN1 were retrospectively evaluated. Twenty patients with evidence of one or more MEN1‐related duodeno‐pancreatic NETs 
ISSN:0300-0664
1365-2265
DOI:10.1111/cen.12411